FDA awards Novartis expanded approval for breast cancer therapy
Posted:
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers.
Waystar has signed a definitive agreement to acquire Iodine Software, a $1.25 billion deal that seeks to empower healthcare payments with more AI capabilities.
Read more here.
Doctors will be able to prescribe a new treatment for people with inflammatory bowel disease (IBD), after the UK medicines watchdog approved guselkumab (Tremfya) for use on the NHS.
Read more here.